Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
- None.
- None.
The FDA's 510(k) clearance for Haemonetics Corporation's TEG® 6s hemostasis analyzer system's new assay cartridge signifies a notable advancement in the medical device sector. This authorization paves the way for the product's commercialization and has the potential to increase Haemonetics' market share in the hemostasis testing market, which is important for patients undergoing procedures where blood management is critical.
From a financial perspective, this clearance could lead to an uptick in sales for Haemonetics, as the TEG 6s system can now cater to a broader patient demographic. The adoption of this technology in both laboratory and point-of-care settings could result in recurrent revenue streams from cartridge sales. However, the actual financial impact will depend on the healthcare providers' adoption rate and the competitive landscape of hemostasis testing solutions.
The enhancement of the TEG 6s system to include the Global Hemostasis-HN assay cartridge represents a strategic move by Haemonetics to solidify its footprint in the viscoelastic testing market. Given the critical nature of hemostasis management in surgeries, particularly those involving cardiopulmonary bypass and liver transplants, there is a significant demand for rapid and accurate testing solutions.
Investors should monitor the adoption curve closely, as well as any potential shifts in market dynamics. It's also important to consider the long-term implications, such as how this innovation might drive standards of care and influence the development of competing technologies. The ability to serve fully heparinized patients could set a new benchmark in the industry, potentially leading to increased market expectations and influencing future regulatory approvals.
The FDA clearance for Haemonetics' new assay cartridge has implications beyond the immediate business impact. It could also contribute to cost savings within the healthcare system by potentially reducing the use of blood products and improving clinical outcomes. Efficient hemostasis management can lead to shorter operation times and decreased need for transfusions, which in turn can translate to lower healthcare costs.
However, the widespread implementation of such technology will require investment in training and integration into existing medical workflows. The long-term economic benefits for healthcare providers will hinge on the balance between these initial costs and the anticipated savings from improved patient management strategies.
"TEG testing provides critical information that can help physicians improve hemostasis management for their patients, especially in critical situations like open heart and liver transplant surgeries and major trauma," said Jan Hartmann, MD, Senior Vice President and Chief Medical Officer at Haemonetics. "The Global Hemostasis-HN assay cartridge expands the benefits of TEG 6s system to patients on cardiopulmonary bypass or undergoing liver transplantation where heparin or endogenous heparinoids are present."
Understanding a patient's complete hemostasis status quickly can have a significant impact on clinical outcomes and use of blood products. Haemonetics' cartridge-based TEG 6s system provides clinicians a complete picture about a patient's coagulation profile, with faster, more detailed information for actionable results compared to conventional coagulation testing. The TEG 6s analyzer is supported by TEG Manager® software that enables remote real-time viewing of results throughout the hospital, as well as Interpretation Guidance with customizable alert messages. Haemonetics is planning to release the new Global Hemostasis-HN cartridge for TEG 6s system in the coming months.
The 510(k) clearance was supported by clinical data from a multi-center trial that included 335 patients undergoing cardiac bypass surgeries, interventional cardiology procedures or liver transplantations. An additional study was conducted using 164 healthy volunteers to establish the normal reference ranges for the test cartridge. Overall, over 5,500 clinical data points were used to demonstrate safety and effectiveness of the Global Hemostasis – HN assays.
"Our market-leading TEG 6s platform has helped Haemonetics make effective and efficient viscoelastic testing more accessible throughout the world," said Stewart Strong, President, Global Hospital at Haemonetics. "With our new cartridge we look forward to expanding the impact of our Blood Management Technologies franchise through increased adoption of TEG 6s, and helping more clinicians improve patient outcomes and standards of care."
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Haemonetics' Global Hospital business provides a range of solutions to address the needs of hospitals, including Interventional Technologies for electrophysiology and interventional cardiology, and Blood Management Technologies that include diagnostics to help inform treatment decisions, technologies to help avoid unnecessary allogeneic transfusions and solutions to help optimize management of blood products. To learn more about Haemonetics, visit www.haemonetics.com.
Cautionary Statement Regarding Forward-Looking Information
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding plans and objectives of management for the operation of Haemonetics, including statements regarding potential benefits associated with the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge and Haemonetics' plans or objectives related to the commercialization of such product enhancement. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, product quality; market acceptance; the effect of global economic and political conditions; and the impact of competitive products and pricing. These and other factors are identified and described in more detail in Haemonetics' periodic reports and other filings with the
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-receives-fda-clearance-for-new-teg-6s-global-hemostasis---hn-cartridge-302108272.html
SOURCE Haemonetics Corporation
FAQ
What FDA clearance did Haemonetics receive?
What are the applications of the new cartridge from Haemonetics?
Who commented on the benefits of TEG testing?
Why is the Global Hemostasis-HN assay cartridge significant?
What impact can understanding a patient's hemostasis status have?
